Engineered Viral Immunotherapy Shows Promise Across Multiple Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics TRANSCRIPT
Download PDFSep 28, 2026
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, discusses the company's virus-based approach for treating multiple tumor types. Their lead therapy is an oral drug and an engineered adenovirus injected into tumors to deliver a gene that educates the patient's immune cells to recognize and eliminate cancer...
Sep 28, 2026
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, discusses the company's virus-based approach for treating multiple tumor types. Their lead therapy is an oral drug and an engineered adenovirus injected into tumors to deliver a gene that educates the patient's immune cells to recognize and eliminate cancer...
Modified Virus Infects Tumors and Activates the Immune System with Mark Bertagnolli ViroMissile TRANSCRIPT
Download PDFFeb 25, 2026
Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the...
Feb 25, 2026
Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the...
DNA Immunotherapy Shows Durable Response in Advanced Melanoma with Phil L’Huillier Scancell TRANSCRIPT
Download PDFOct 30, 2025
Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care...